Objectives and study aims Recent pilot studies have assessed the feasibility of a novel 1.9-/1.5-mu m dual emission endoscopic laser treatment (1.9-/1.5-mu mDEELT) for endoscopic hemostasis, ablation and resection. In this study, we investigated the safety and efficacy of 1.9-/1.5-mu mDEELT in patients with chronic anemia due to gastrointestinal vascular lesions in a real-life multicenter cohort setting. Patients and methods Consecutive patients with moderate/severe iron-deficiency anemia undergoing 1.9-/1.5-mu mDEELT for upper and lower gastrointestinal bleeding due to vascular lesions were enrolled in three academic referral centers. Safety and successful ablation of vascular lesions were the primary outcomes. Long-term hemoglobin level, blood transfusion requirements, endoscopic severity scores of complex vascular disorders and technical lasing parameters were also assessed. Long-term hemoglobin variations have been further assessed, with repeated measure analysis of variance and univariate analyses. Results Fifty patients (median age 74; range 47 to 91 years) with gastric antral vascular ectasia (GAVE) (22), angioectasia (22) and radiation proctopathy (6) underwent 58 1.9-/1.5-mu mDEELT between 2016 and 2020.A11 procedures were technically feasible leading to successful ablation of the targeted lesion/s, with no incident or adverse event potentially related to the 1.9-/1.5-mu mDEELT technique. Within a 6-month follow-up, hemoglobin values significantly rose (+1.77 at 1 month and + 1.70 0:IL at 6 months, P<0.01), the blood supply requirement decreased (at least one transfusion in 32 versus 13 patients, P<0.01), and GAVE lesions showed a clear endoscopic improvement (from 5 points to 1 points, P<0.01). Conclusions The 1.9-/1.5-mu m laser system is a safe and effective endoscopic tool for haemostatic ablation of bleeding vascular lesions within the gastrointestinal tract in tertiary referral centers.
Safety and efficacy of dual emission endoscopic laser treatment in patients with upper or lower gastrointestinal vascular lesions causing chronic anemia: results from the first multicenter cohort study / G. Tontini, L. Dioscoridi, A. Rimondi, P. Cantù, F. Cavallaro, A. Giannetti, L. Elli, L. Pastorelli, F. Pugliese, M. Mutignani, M. Vecchi. - In: ENDOSCOPY INTERNATIONAL OPEN. - ISSN 2364-3722. - 10:4(2022 Apr 14), pp. E386-E393. [10.1055/a-1781-7066]
Safety and efficacy of dual emission endoscopic laser treatment in patients with upper or lower gastrointestinal vascular lesions causing chronic anemia: results from the first multicenter cohort study
G. Tontini
Primo
;A. RimondiSecondo
;F. Cavallaro;L. Elli;L. Pastorelli;M. VecchiUltimo
2022
Abstract
Objectives and study aims Recent pilot studies have assessed the feasibility of a novel 1.9-/1.5-mu m dual emission endoscopic laser treatment (1.9-/1.5-mu mDEELT) for endoscopic hemostasis, ablation and resection. In this study, we investigated the safety and efficacy of 1.9-/1.5-mu mDEELT in patients with chronic anemia due to gastrointestinal vascular lesions in a real-life multicenter cohort setting. Patients and methods Consecutive patients with moderate/severe iron-deficiency anemia undergoing 1.9-/1.5-mu mDEELT for upper and lower gastrointestinal bleeding due to vascular lesions were enrolled in three academic referral centers. Safety and successful ablation of vascular lesions were the primary outcomes. Long-term hemoglobin level, blood transfusion requirements, endoscopic severity scores of complex vascular disorders and technical lasing parameters were also assessed. Long-term hemoglobin variations have been further assessed, with repeated measure analysis of variance and univariate analyses. Results Fifty patients (median age 74; range 47 to 91 years) with gastric antral vascular ectasia (GAVE) (22), angioectasia (22) and radiation proctopathy (6) underwent 58 1.9-/1.5-mu mDEELT between 2016 and 2020.A11 procedures were technically feasible leading to successful ablation of the targeted lesion/s, with no incident or adverse event potentially related to the 1.9-/1.5-mu mDEELT technique. Within a 6-month follow-up, hemoglobin values significantly rose (+1.77 at 1 month and + 1.70 0:IL at 6 months, P<0.01), the blood supply requirement decreased (at least one transfusion in 32 versus 13 patients, P<0.01), and GAVE lesions showed a clear endoscopic improvement (from 5 points to 1 points, P<0.01). Conclusions The 1.9-/1.5-mu m laser system is a safe and effective endoscopic tool for haemostatic ablation of bleeding vascular lesions within the gastrointestinal tract in tertiary referral centers.File | Dimensione | Formato | |
---|---|---|---|
DEELT in Upper&LowerGI_EIO 2022.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.06 MB
Formato
Adobe PDF
|
1.06 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.